Sugi Predict

Sugi Predict / Compounds / SCHEMBL5234871

SCHEMBL5234871

SCHEMBL5234871

COc1cc(S(=O)(=O)N2CCC(C(=O)O)CC2)ccc1-c1nc2c(c(C3CCCCC3)nn2C)c(=O)[nH]1

nearest known ligand 0.64

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ PDE7A Q13946 13/20 0.64
▸ PDE5A O76074 3/20 0.46
▸ PDE1A P54750 2/20 0.46
▸ PDE1B Q01064 2/20 0.46
▸ PDE1C Q14123 2/20 0.46
▸ APEX1 P27695 1/20 0.46
▸ EPHX2 P34913 1/20 0.45
▸ PDE7B Q9NP56 2/20 0.44
▸ TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5230428 0.92 PDE7A (0.67) PDE7APDE5APDE1APDE1BPDE1C
SCHEMBL5228438 0.91 PDE7A (0.60) PDE7APDE5APDE1APDE1BPDE1C
SCHEMBL5235405 0.90 PDE7A (0.70) PDE7APDE5APDE1APDE1BPDE1C
SCHEMBL5231356 0.90 PDE7A (0.69) PDE7APDE5APDE1APDE1BPDE1C
Hydrochloric Acid SCHEMBL5228893 0.89 PDE7A (0.68) PDE7APDE5APDE1APDE1BPDE1C
SCHEMBL5232171 0.89 PDE7A (0.68) PDE7APDE5APDE1APDE1BPDE1C
SCHEMBL5273342 0.89 PDE7A (0.66) PDE7APDE5APDE1APDE1BPDE1C
SCHEMBL5231573 0.89 PDE7A (0.65) PDE7APDE5APDE1APDE1BPDE1C
SCHEMBL5232725 0.89 PDE7A (0.65) PDE7APDE5APDE1APDE1BPDE1C
SCHEMBL5230304 0.89 PDE7A (0.68) PDE7APDE5APDE1APDE1BPDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 — — EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 — — US disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 — — US disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 — — US disclosed
CN-1264843-C Pyrazolopyrimidinone derivatives having PDE7 inhibitory action DAIICHI SUNTORY PHARMACEUTICAL (JP) 2006-07-19 — — CN disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 — — US disclosed
CN-1533392-A Pyrazolopgrimidinone derivatives having PED 7 inhibitory activity ��һ��������ҩ��ʽ���� 2004-09-29 — — CN disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A PDE7A 4/4885PDE5A 8/4885PDE1A 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.